Sarepta Therapeutics, Inc. (SRPT) News
Filter SRPT News Items
SRPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRPT News Highlights
- For SRPT, its 30 day story count is now at 15.
- Over the past 22 days, the trend for SRPT's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- AGE, DNLI and EAR are the most mentioned tickers in articles about SRPT.
Latest SRPT News From Around the Web
Below are the latest news stories about SAREPTA THERAPEUTICS INC that investors may wish to consider to help them evaluate SRPT as an investment opportunity.
3 Things About Sarepta Therapeutics Every Smart Investor KnowsMastering this stock requires appreciating a few scientific nuances. |
15 Best Fast Growth Stocks to Buy NowIn this article, we will take a look at the 15 best fast growth stocks to buy now. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Best Fast Growth Stocks to Buy Now. Vanguard Growth ETF is one of the most famous growth focused […] |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the DayFluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article. |
Sarepta Therapeutics Seen Expanding Duchenne Treatment LabelSarepta Therapeutics may be on the cusp of expanding the label for its Duchenne Muscular Dystrophy treatment, according to Mizuho analyst Uy Ear. The company has submitted an efficacy supplement to the FDA for Elevidys, requesting expanded approval for all DMD patients. The treatment's current label restricts its use to 4- to 5-year-old ambulatory patients. |
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?Both develop medicines for rare diseases, and each aims to conquer a niche market. |
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024. |
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory StatusCAMBRIDGE, Mass., December 22, 2023--Sarepta submits efficacy supplement to expand ELEVIDYS label to include Duchenne patients without restriction to age or ambulatory status |
Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approvalThe biotech is asking the agency to clear its treatment Elevidys in more patients with the disease, despite a confirmatory trial that missed its main goal. |
An Intrinsic Calculation For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Suggests It's 42% UndervaluedKey Insights Using the 2 Stage Free Cash Flow to Equity, Sarepta Therapeutics fair value estimate is US$155 Current... |